Last 66,600 KRW
Change Today -600.00 / -0.89%
Volume 13.4K
069620 On Other Exchanges
Symbol
Exchange
Korea SE
As of 1:10 AM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for daewoong pharmaceutical co (069620)

Year over year, Daewoong Pharmaceutical Co., Ltd. has seen revenues remain relatively flat (669.0B KRW to 682.5B KRW), though the company was able to grow net income from 34.1B KRW to 58.4B KRW. A reduction in the percentage of sales devoted to selling, general and administrative costs from 31.44% to 27.85% was a key component in the bottom line growth in the face of flat revenues.
View Income Statement In U.S. Dollar
Currency in
Millions of South Korean Wons
As of:Dec 31
2010
Press
Release

KRW
Dec 31
2011
KRW
Dec 31
2012
KRW
Dec 31
2013
KRW
4 Year
Trend
Revenues683,330.4710,547.1669,013.8682,508.0
Other Revenues--0.0--0.0
TOTAL REVENUES683,330.4710,547.1669,013.8682,508.0
Cost of Goods Sold380,555.4411,283.3394,081.5392,196.8
GROSS PROFIT302,775.0299,263.9274,932.3290,311.2
Selling General & Admin Expenses, Total205,150.9212,769.4210,369.3190,099.6
R&D Expenses--19,519.619,643.121,169.5
Depreciation & Amortization, Total--4,798.25,367.64,767.7
Other Operating Expenses--2,498.02,669.42,902.8
OTHER OPERATING EXPENSES, TOTAL205,150.9239,585.2238,049.5218,939.6
OPERATING INCOME97,624.259,678.736,882.871,371.6
Interest Expense-7,339.1-3,208.3-735.5-599.3
Interest and Investment Income8,883.02,241.1539.22,232.6
NET INTEREST EXPENSE1,543.9-967.2-196.31,633.3
Income (Loss) on Equity Investments-200.093.41,998.6-219.3
Currency Exchange Gains (Loss)--6,297.8842.2818.7
Other Non-Operating Income (Expenses)-8,765.6-2,966.24,546.04,613.3
EBT, EXCLUDING UNUSUAL ITEMS90,202.462,136.444,073.378,217.6
Gain (Loss) on Sale of Investments--1,738.3-1,529.7-3,873.5
Gain (Loss) on Sale of Assets--100.0-211.0-102.3
Other Unusual Items, Total-----607.4-239.2
EBT, INCLUDING UNUSUAL ITEMS90,202.463,974.741,725.274,002.6
Income Tax Expense66,297.313,246.68,212.316,028.2
Minority Interest in Earnings-377.9-542.2566.4425.2
Earnings from Continuing Operations23,905.150,728.133,512.957,974.4
NET INCOME23,527.250,185.934,079.358,399.6
NET INCOME TO COMMON INCLUDING EXTRA ITEMS23,527.250,185.934,079.358,399.6
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS23,527.250,185.934,079.358,399.6
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
069620:KS 66,600.00 KRW -600.00

069620 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 069620.
View Industry Companies
 

Industry Analysis

069620

Industry Average

Valuation 069620 Industry Range
Price/Earnings 11.2x
Price/Sales 0.9x
Price/Book 1.4x
Price/Cash Flow 11.6x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAEWOONG PHARMACEUTICAL CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.